Meiho University Institutional Repository:Item 987654321/2171
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 2878/3796 (76%)
Visitors : 3953268      Online Users : 770
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.meiho.edu.tw/ir/handle/987654321/2171


    Title: Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention
    Authors: Tsai TH;Sung PH;Chang LT;Sun CK;Yeh KH;Chung SY;Chua S;Chen YL;Wu CJ;Chang HW;Ko SF;Yip HK
    Date: 2012
    Issue Date: 2013-10-03T07:42:50Z (UTC)
    Abstract: AIM:
    This study investigated the impact of the circulating galectin-3 level on the 30-day prognostic outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
    METHODS:
    From May 2009 to March 2011, blood samples for assessment of the circulating galectin-3 level were collected from 196 consecutive STEMI patients treated by primary PCI and from 30 healthy volunteers.
    RESULTS:
    The galectin-3 level was determined using ELISA. Our results demonstrated that the circulating level of galectin-3 was significantly higher in STEMI patients than in healthy control subjects (p<0.001). As compared with patients with galectin-3 <7.67 ng/mL, patients with galectin-3 ≥7.67 ng/mL were significantly older, had significantly lower left ventricular ejection fraction and significantly higher frequency of elevated white blood cell count, advanced Killip score (defined as ≥ score 3), congestive heart failure (defined as ≥ New York Heart Association Functional Class III), respiratory failure, unstable hemodynamics requiring a mechanical ventilator and intra-aortic balloon pump support, multiple vessel diseases and 30-day mortality (all p<0.04). Furthermore, multivariate analysis showed that elevated circulating level of galectin-3 was the strongest independent predictor of the combined 30-day major adverse clinical outcome (MACO) (defined as advanced CHF or 30-day mortality) (p<0.0001).
    CONCLUSION:
    A high circulating galectin-3 level may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.
    Relation: J Atheroscler Thromb. 2012;19(12):1073-82
    Appears in Collections:[Department of Nursing] Papers

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML1129View/Open


    All items in MUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback